To examine the association between rate of initial β-hCG rise following fresh in-vitro fertilization (IVF) cycles and long-term pregnancy complications.

Preconception health status, especially of women, but also of men, is known to influence pregnancy outcomes. Despite knowledge of the growing importance of preconception health, numerous challenges remain for conducting research in this population and delivering appropriate clinical care. The 2023 Global Pregnancy Collaboration annual workshop focused on exploring preconception health as it relates to adverse pregnancy outcomes. Here we summarize the proceedings and the current state of the science. We particularly focus on quantifying the exposome as a rich target for investigation of factors that increase the risk for and/ or contribute to preeclampsia and other adverse pregnancy outcomes. We conclude with recommendations for the scientific and clinical community to address knowledge gaps regarding the links between preconception health and adverse pregnancy outcomes.

The prevalence of maternal chronic hypertension is on the rise. Hypertensive disorders of pregnancy are associated with adverse pregnancy and neonatal outcomes; however, offspring long-term outcomes are less investigated. We evaluated the long-term neurological morbidity of offspring exposed in-utero to maternal chronic hypertension, unrelated to preeclampsia.

Hypertensive disorders of pregnancy (HDP) are a leading cause of maternal morbidity and mortality. While a healthy diet may reduce the risk of HDP, dietary counseling at obstetric visits is rare. The goal of this study was to evaluate provider perspectives and rates of dietary counseling among obstetric patients with HDP and related conditions such as obesity.

To investigate the safety and clinical effectiveness of telemonitoring of blood pressure and symptoms with SAFE@home combined with a hybrid care path in patients at increased risk of or with established hypertensive disorders of pregnancy, compared to usual care.

This study applies a decision analysis metric, the Minimum Test Tradeoff (MTT), to determine the minimum number of data collections of uterine artery pulsatility index (UTPI) per true positive prediction of preeclampsia to increase the expected utility of prediction.

This study evaluates the sFlt-1/PlGF ratio for predicting preeclampsia (PE)-related maternal or fetal adverse outcomes (AOs) and PE-related delivery within 1-2 weeks in twin pregnancies with suspected PE and fetal growth restriction (FGR).

To identify factors associated with uncontrolled blood pressure (BP) in preeclamptic women receiving antihypertensive therapy in the South Gondar Zone, Northwest Ethiopia.

Preeclampsia and eclampsia, hypertensive disorders of pregnancy, significantly contribute to maternal and perinatal morbidity and mortality in low- and middle-income countries like Uganda. Comprehensive data on their prevalence and determinants in Uganda's tertiary healthcare facilities are limited. A systematic review was conducted searching PubMed, Lens.org, and Google Scholar for observational studies from Ugandan tertiary hospitals published between January 2015 and March 2025. Due to heterogeneity, a narrative synthesis was performed using the Synthesis without Meta-analysis (SWiM) framework, with study quality assessed via the Newcastle-Ottawa Scale. Ten studies, primarily from Mulago and Mbarara hospitals, met the final inclusion criteria. Limited population-based prevalence data were available, with one study reporting preeclampsia prevalence of 4.3 %. Key determinants included young maternal age, nulliparity, and delayed care-seeking. Complications such as HELLP syndrome (18.6 %) and non-proteinuric preeclampsia (24.6 %) were frequent, with systemic challenges like limited laboratory capacity noted. Preeclampsia and eclampsia impose a substantial burden in Uganda's tertiary facilities, necessitating enhanced antenatal screening and timely referral. The scarcity of standardized prevalence data underscores the need for broader epidemiological surveillance.

To assess the clinical factors linked to maternal mortality due to preeclampsia (PE) in Indonesia, spanning from risk factors to maternal and perinatal outcomes. Our objective is to offer valuable insights that can be used to enhance healthcare policies and interventions for pregnant women in Indonesia.

To examine adherence to antihypertensive medications during pregnancy and postpartum among patients with hypertensive disorders of pregnancy (HDP)..

Magnesium sulfate (MgSO4) is the standard drug for treatment of eclampsia, and to prevent its occurrence in women with preeclampsia with severe features, however, the ideal postpartum treatment duration remains unclear.

The global burden of pre-eclampsia is rising, posing significant challenges to women's health, particularly in cases of multiple organ failure. It continues to contribute to 14 % of maternal deaths during pregnancy, with co-morbidities further complicating maternal and fetal outcomes. Risk assessment in pre-eclampsia (early and late) is critical. It remains a challenge due to the limitations of non-specific biomarkers and the discomfort associated with invasive diagnostic tests, making them unsuitable for remote settings. This study explores the integration of advanced machine learning (ML) models for analyzing urine- and serum-based biomarkers to enhance predictive accuracy. ML algorithms, including CatBoost, LightGBM, XGBoost, and Random Forest (RF), were evaluated using clinical datasets of 11,006 pregnant women from Yonsei University Healthcare Centre. The study findings indicate that CatBoost achieved the highest accuracy (∼92.12 % with 10-fold cross-validation), followed closely by RF, LightGBM, and XGBoost. Feature importance plots demonstrated the relevance of selected features in enhancing diagnostic precision. These results underscore the potential of ML-driven analysis for risk assessment and associated diagnosis in variable real-time resource settings, improving maternal and fetal health outcomes in pre-eclampsia.

Preeclampsia, a medical complication of pregnancy, is associated with central nervous system (CNS) signs and symptoms, such as headache, hyperexcitability, hyperreflexia, visual disturbances, and seizures (referred to as eclampsia). We hypothesized that markers of neurological injury such as plasma neurofilaments comprising light chains (NfL) and phosphorylated heavy chains (pNfH), would be elevated in preeclampsia and could serve as biomarkers of severity of preeclampsia.

Even though some underlying biological mechanisms and epidemiological evidence are still unclear, sexual dimorphism seems to play an important role in obstetric complications such as preeclampsia. Parity status has not been frequently considered in determining the risk of preeclampsia in previous studies. This study aimed to determine the association between fetal sex and preeclampsia, stratified by parity status.

To examine fetal growth patterns in preeclampsia (PE) and compare them with a control, low-risk Indian population.

Hypertensive disorders contribute significantly to maternal morbidity and mortality. We sought to evaluate the impact of a clinical decision-support (CDS) system on maternal hypertension treatment. The CDS (GE HealthCare, Chicago, IL, USA) utilized digital CDS algorithms based on the American College of Obstetrics and Gynecology maternal hypertension treatment protocols.

Pre-eclampsia is a hypertensive disorder of pregnancy which, left untreated, can cause significant foeto-maternal morbidity. Accordingly, the National Institution for Health and Care Excellence (NICE) recommends that high-risk women be prescribed daily prophylaxis with 75-150 mg aspirin from 12 weeks gestation until delivery. NICE stratifies risk using 11 maternal risk factors; however, to date, the diagnostic accuracy of this system has never been evaluated by meta-analytic review. Our systematic review and meta-analysis evaluates the sensitivity and specificity of the NICE risk-stratification algorithm in predicting pre-eclampsia in pregnant women ≥ 16 years. Systematic searches of PubMed, Cochrane Library and SCOPUS identified 894,527 pregnancies from 20 eligible studies with a CBEM Level of Evidence ≤ 4. The logit-transformed sensitivities and specificities from each study were modelled as a bivariate distribution with random effects to generate restricted maximum-likelihood estimates (MLEs) for the overall sensitivity and specificity of the algorithm in predicting pre-eclampsia. These estimates were 43.3 % (95 % CI 32.6-54.7) and 91.0 % (95 % CI 84.0-95.1), respectively. Significant heterogeneity was exhibited between the sensitivities (I = 93.2 %) and specificities (I = 98.0 %) calculated by each of the included studies and, consequently, there is a low degree of certainty in these estimates. Overall, the NICE risk-stratification algorithm performs remarkably poorly when used to predict pre-eclampsia in any of 3 gestational categories. Clinicians should advise women that the post-test probabilities of pre-eclampsia are 1 in 4 for high-risk patients and 1 in 25 for low-risk patients (assuming a moderate incidence of 6 %; see Appendix S3), although future studies are likely to alter these statistics.

To ensure a successful pregnancy, a delicate immunological balance is essential at the feto-maternal interface. Dysregulation of the complement system is linked to adverse pregnancy outcomes such as fetal growth restriction, preeclampsia and preterm birth. However, it is unknown how this translates into umbilical cord concentrations of complement factors.